DALLAS, TEXAS : StockGuru announces that Adamis Pharmaceuticals Corp. (OTCBB: ADMP) is in the StockGuru Spotlight.    Adamis Pharmaceuticals has two wholly-owned subsidiaries: Adamis Laboratories and Adamis Therapeutics Inc. (formerly Adamis Viral Therapies). Adamis Labs has niche prescription products in the allergy and respiratory therapeutic area and intends to launch additional products in this area. Currently, Adamis Therapeutics is primarily focused on the development of patented, proprietary technologies for the potential treatment of human prostate cancer.

On Thursday, the company put out news announcing that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells. Pancreatic cancer still remains one of the most deadly forms of all cancers. The mortality from pancreatic cancer compares strikingly with its incidence. It has one of the worst prognoses with an overall survival rate of less than 5% and with most of the patients dying within the first two years. Recent results regarding the mechanism leading to the occurrence of pancreatic cancer suggest that in more than 90% of pancreatic cancers the Ras oncogene has been mutated. The mutation of the Ras oncoprotein has been linked to the induction of multiple signaling pathways within the cell which leads to the resistance of those cells to apoptosis (cell death) and the emergence of cancer.
 

Shares for Adamis Pharmaceuticals Corp. were up during the afternoon of trading on Thursday and closed slightly up at closing.

To view the StockGuru Spotlight on Adamis Pharmaceuticals Corp. (OTCBB: ADMP), please visit: http://stockguru.com/category/latest-spotlights/

To get free alerts on this and other similar stocks, please register here:

Get StockGuru Email Alerts

What is the StockGuru Spotlight? 

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight.  Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage.  There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below.   StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected].  If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact the StockGuru Publisher John Pentony at this email address:  [email protected].

Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions.  SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.  

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occassionally compensated for coverage.  When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present.  Additionally SG also discloses any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
 

John Pentony, Publisher, Stockguru.com Tel: +1 469 252 3031 e-mail: [email protected]